Ozempic Maker Novo Nordisk Lowers Growth Outlook of Its Blockbuster Drugs
Intensifying competition, pricing pressure and copycat versions of Ozempic and Wegovy are holding back sales at the pharma giant.
(The Wall Street Journal, 2025-11-05T08:17:00Z)